Lapatinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
|- | |- | ||
! colspan="6" align="center"| | ! colspan="6" align="center"| Tyrosine Kinase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>PMC:2679105</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
Revision as of 07:56, 6 December 2010
Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1] | |||||
|---|---|---|---|---|---|
| Parameter | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Tmax (hr) | 4 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Cmax (ng/ml) | 115 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Bioavailability (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Protein Binding (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| T1/2 (hr) | 9.6 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| AUC (ng/ml/hr) | 1429 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| IC50 (nM) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Dosage (mg) | 100 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Metabolism | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
- ↑ PMC:2679105
